retatrutide update october 2025 27, 2025: U.K. regulators bust illicit site making unlicensed and tirzepatide pens – Partnership for Safe Medicines Have you had the opportunity

For example, a literature review performed in 2024 found only two case reports of GLP-1 RAs for treating HS that met the inclusion criteria

Sweating typically subsides once your body acclimates

Meanwhile, a post-hoc analysis of the STEP 1 and STEP 4 trials showed that semaglutide 2.4 mg was associated with an approximately 60% reduction of the 10-years risk of T2D according to the Cardiometabolic Disease Staging (CMDS) calculator, regardless of patients baseline glycemic status 74

Most providers use standardized questionnaires to track nausea, vomiting, diarrhea, and other gastrointestinal symptoms

Approved GLP-1 RAs: Indications and Administration Dulaglutide (Trulicity) (injection weekly) Type 2 Diabetes Exenatide extended-release (Bydureon bcise) (injection weekly) Type 2 Diabetes Exenatide (Byetta) (injection twice daily) Type 2 Diabetes Semaglutide (Ozempic) (injection weekly) Type 2 Diabetes Liraglutide (Victoza, Saxenda) (injection daily) Obesity and Type 2 Diabetes, Respectively Lixisenatide (Adlyxin) (injection daily) Type 2 Diabetes Semaglutide (Rybelsus) (taken by mouth once daily) Obesity Semaglutide (Wegovy) (injection weekly) Obesity Tirzepatide* (Mounjaro, Zepbound)(injection weekly) Type 2 Diabetes and Obesity, Respectively View the FDAs up-to-date list of approved GLP-1 RAs Cardiovascular Risk Reduction Benefits of GLP-1 RAs for Patients with T2D 2 to 4 times more likely to develop cardiovascular disease (CVD) than those without T2D